Target intelligence / Profile preview

Patient-specific tumor-derived peptide–MHC complexes (pMHC)

Target
pMHC
Molecular classification
Receptor, Other
01

Overview

Patient-specific tumor-derived peptide–MHC (pMHC) complexes are cell-surface structures consisting of major histocompatibility complex molecules presenting short, mutated, or aberrantly expressed peptides derived from intracellular tumor proteins. These complexes serve as critical immunological beacons that allow the adaptive immune system, specifically T-cell receptors (TCRs) on cytotoxic T lymphocytes (CTLs), to distinguish malignant cells from healthy tissue. In cancer immunotherapy, these complexes are targeted to elicit highly precise, patient-specific immune responses. Personalized therapeutic approaches, such as autologous total tumor RNA-loaded dendritic cell vaccines, exploit this mechanism by introducing tumor-derived genetic material into a patient's dendritic cells. This process enables the presentation of a diverse array of patient-specific tumor antigens, thereby priming and activating CTLs to selectively recognize and destroy tumor cells expressing the corresponding pMHC complexes.

Other names
Patient-specific tumor-derived peptide-MHC complexesTumor-derived peptide-MHC complexesTumor-specific peptide-MHC complexesTumor-derived peptide-HLA complexespHLA complexespMHC complexes
02

Mechanism of action

Stimulation of patient-specific cytotoxic T-lymphocyte (CTL) responses by presenting a broad repertoire of tumor-associated antigens (TAAs) on major histocompatibility complex (MHC) molecules, leading to targeted tumor cell lysis.

03

Biological functions

Immune responseAntigen presentation
04

Disease associations

Cancer
05

Safety considerations

Autoimmunity or off-target immune attack against healthy tissues sharing similar epitopesCytokine release syndrome (CRS)Tumor immune evasion via downregulation of MHC molecules or antigen lossHigh manufacturing complexity and inter-patient variability
06

Interacting drugs

07

Biomarkers

Tumor mutational burden (TMB)HLA haplotypeInterferon-gamma (IFN-g) secretionAntigen-specific T-cell frequency

Beyond the preview

Go deeper on Patient-specific tumor-derived peptide–MHC complexes (pMHC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Patient-specific tumor-derived peptide–MHC complexes (pMHC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call